Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Special report
: The Fierce 50 of 2024
in vivo
Biotech
Sanofi, Scribe seal new in vivo collab worth more than $1.2B
Sanofi and Scribe have sealed a second partnership in less than a year, with the latest pact focused on developing in vivo gene editing therapies.
Max Bayer
Jul 17, 2023 11:30am
George Church-founded biotech tacks on $40M series A
Jul 14, 2022 8:00am
Novartis pays $75M to form sickle cell in vivo gene editing pact
Jun 22, 2022 3:40am
Moderna, Excision each enter HIV battle with mRNA, CRISPR tech
Jan 27, 2022 11:02am
Sana inks $204M biobucks pact with IASO, Innovent for CAR access
Jan 11, 2022 3:00pm
Mammoth, Vertex ink $650M biobucks deal for CRISPR gene editing
Oct 26, 2021 9:00am
